BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Feds Close Investigation into Medtronic, Inc. (MDT)'s Marketing of Infuse


5/17/2012 8:54:39 AM

Minneapolis / St. Paul Business Journal by Ed Stych, Web Producer

Medtronic Inc. said Wednesday that federal prosecutors have closed their four-year investigation into the medical device company's marketing of its Infuse bone-growth product.

The investigation by the U.S. Department of Justice (DOJ) and the U.S. Attorney's Office in Massachusetts started in October 2008, Medtronic spokeswoman Cindy Resman said. She said the prosecutors received notification that they have closed the civil and criminal investigations. There was no finding of wrongdoing.

The DOJ began its investigation in 2008 into uses of Infuse that were considered "off-label" — which means uses not approved by the Food and Drug Administration (FDA). It's OK for doctors to use device such as Infuse off-label, but the manufacturers can't promote that use.

The investigation apparently widened last year after Medtronic's clinical trials were criticized by some spine doctors and U.S. senators. They claimed Infuse isn't as safe as Medtronic says and that Medtronic's paid trials led to biased results. Yale University is currently reviewing the safety of the spine product. Medtronic is paying the school $2.5 million for an independent review.

In March, Fridley-based Medtronic (NYSE: MDT) agreed to pay $85 million to settle a shareholders lawsuit over the marketing of Infuse, although Medtronic denied it engaged in wrongdoing.

The 2008 suit claimed that Medtronic failed to reveal that as much as 85 percent of Infuse sales were dependent on off-label sales.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->